Genesoft and Genome Therapeutics announce definite merger agreement

Published: 2003-11-21 07:00:00

Updated: 2003-11-21 07:00:00

Genome Therapeutics (Nasdaq: GENE) and Genesoft Pharmaceuticals Inc. entered into a definite agreement to merge in all-stock transaction on November 18 (ET).

This merger agreement has been approved by the Board of Director at both Genome Therapeutics and Genesoft Pharmaceuticals. Genome Therap...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK